Summary
Prostate cancer is the most commonly diagnosed cancer among men, with an anticipated 1.7M new cases and 499,000 deaths by 2030 worldwide. Although, most cancer therapies available focus on treatment of the primary tumor, the leading cause of cancer morbidity and mortality is metastasis. Today’s current treatments for metastatic prostate cancer focus on later stage of the cancer progression, when the signs of metastasis spread are already observed; and modestly prolong the patient’s survival and have serious side effects. Therefore, there is a high unmet need for new therapies, which can effectively address the problem as the first adjuvant treatment against early stage of metastasis in prostate cancer.
RhoVac is a biotechnology company dedicated to the research and development of immunotherapies for the treatment of early stage metastatic cancer. The RV001 (RhoVac’s first product) vaccine is the first therapeutic vaccine against metastatic cancer cells, specifically targeting the prevention of cancer relapses. The concept behind RV001 relies on the reprogramming of the patient own T cells to recognise and eliminate early stage metastatic cancer cells.
Together with an unprecedented therapeutic potential in multiple cancer types, RV001 holds important competitive advantages, such as safety, tolerability and cost-effectiveness. However, to secure swift development and successful commercialization, RhoVac needs partnerships and capital to achieve RV001 clinical validation. In this context, we believe SME instrument will be crucial to position RV001 within the metastatic cancer treatment and to confirm the high pharma-economic value of our disruptive technology. The accomplishment of SME Phase 1 and Phase 2 project objectives will maximize the clinical value of our vaccine within the selected market and a lead to a significant business opportunity for RhoVac – revenues are expected to be around €350M, within 5 years of market approval, only in prostate cancer segment.
RhoVac is a biotechnology company dedicated to the research and development of immunotherapies for the treatment of early stage metastatic cancer. The RV001 (RhoVac’s first product) vaccine is the first therapeutic vaccine against metastatic cancer cells, specifically targeting the prevention of cancer relapses. The concept behind RV001 relies on the reprogramming of the patient own T cells to recognise and eliminate early stage metastatic cancer cells.
Together with an unprecedented therapeutic potential in multiple cancer types, RV001 holds important competitive advantages, such as safety, tolerability and cost-effectiveness. However, to secure swift development and successful commercialization, RhoVac needs partnerships and capital to achieve RV001 clinical validation. In this context, we believe SME instrument will be crucial to position RV001 within the metastatic cancer treatment and to confirm the high pharma-economic value of our disruptive technology. The accomplishment of SME Phase 1 and Phase 2 project objectives will maximize the clinical value of our vaccine within the selected market and a lead to a significant business opportunity for RhoVac – revenues are expected to be around €350M, within 5 years of market approval, only in prostate cancer segment.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/816773 |
| Start date: | 01-04-2018 |
| End date: | 30-09-2018 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Prostate cancer is the most commonly diagnosed cancer among men, with an anticipated 1.7M new cases and 499,000 deaths by 2030 worldwide. Although, most cancer therapies available focus on treatment of the primary tumor, the leading cause of cancer morbidity and mortality is metastasis. Today’s current treatments for metastatic prostate cancer focus on later stage of the cancer progression, when the signs of metastasis spread are already observed; and modestly prolong the patient’s survival and have serious side effects. Therefore, there is a high unmet need for new therapies, which can effectively address the problem as the first adjuvant treatment against early stage of metastasis in prostate cancer.RhoVac is a biotechnology company dedicated to the research and development of immunotherapies for the treatment of early stage metastatic cancer. The RV001 (RhoVac’s first product) vaccine is the first therapeutic vaccine against metastatic cancer cells, specifically targeting the prevention of cancer relapses. The concept behind RV001 relies on the reprogramming of the patient own T cells to recognise and eliminate early stage metastatic cancer cells.
Together with an unprecedented therapeutic potential in multiple cancer types, RV001 holds important competitive advantages, such as safety, tolerability and cost-effectiveness. However, to secure swift development and successful commercialization, RhoVac needs partnerships and capital to achieve RV001 clinical validation. In this context, we believe SME instrument will be crucial to position RV001 within the metastatic cancer treatment and to confirm the high pharma-economic value of our disruptive technology. The accomplishment of SME Phase 1 and Phase 2 project objectives will maximize the clinical value of our vaccine within the selected market and a lead to a significant business opportunity for RhoVac – revenues are expected to be around €350M, within 5 years of market approval, only in prostate cancer segment.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
